Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02765165 : Phase 1/2 Study of USL311 Alone and in Combination With Lomustine in Subjects With Advanced Solid Tumors and Relapsed/Recurrent Glioblastoma Multiforme (GBM)
PhasePhase 1/Phase 2
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

All Subjects:

1. Provide signed and dated informed consent prior to study-specific screening
procedures

2. ? 18 years old

3. Karnofsky performance status (KPS) ? 70

4. Must have adequate bone marrow and renal/hepatic function within protocol specified
limits

5. Disease-free period of > 2 years from any other previous malignancies, excluding
curatively treated basal cell carcinoma, squamous cell carcinoma of the skin, or
carcinoma in situ of the cervix. Subjects with prostate cancer Stage 1 that do not
require treatment may also be included

6. Women and men must use protocol approved methods of contraception

7. Must be able and willing to comply with the study visit schedule and study procedures

8. Must have available archived tumor tissue and willing and able to provide consent for
study access to such tissue

For Phase 1 Subjects Only:

9. Histologically or cytologically documented diagnosis of solid tumor for which no
standard therapy is recognized or have failed or intolerant to the standard-of-care
treatment

10. Inoperable metastatic or locally advanced, unresectable disease

11. Subjects may have either evaluable or measurable disease

12. Subjects with treated (surgically excised or irradiated) and stable brain metastases
are eligible as long as the subject has adequately recovered from treatment and the
treatment was ? 28 days prior to initiation of study drug(s) and baseline brain
computed tomography (CT) with contrast or magnetic resonance imaging (MRI) ? 14 days
of initiation of study drug is negative for new brain metastases

For Phase 2 Subjects Only:

13. Histologically confirmed diagnosis of GBM

14. Subjects must have documented recurrence after first-line treatment

15. Prior first-line treatment must have included radiation and temozolomide

16. Subject is suitable for re-resection, per Investigator discretion, as a component of
their clinical care

17. No more than one prior resection (Note: biopsy does not count as prior resection)

Exclusion Criteria:

All Subjects

1. Subjects who have had recent systemic anticancer therapies, interventional device
treatment and/or radiotherapy either within 14 days prior to first dose of study
drug(s) or have not recovered (to grade ? 1) from all clinically significant
toxicities related to prior therapies

2. Subjects who have had any major surgery (not including re-resection surgery required
in Phase 2) within 28 days prior to first dose of study drug(s), or minor surgery
within 14 days prior to first day of study drug(s)

3. Subjects taking any protocol prohibited medications within 14 days prior to
initiating study drug(s) treatment

4. Subjects who have been treated with an investigational agent or investigational
interventional device within 21 days prior to the first dose of study drug(s)

5. History of significant cardiac disease

6. Pregnant or breastfeeding

7. Any other significant co-morbid conditions that in the opinion of the Investigator
would impair study participation or cooperation

For Phase 1 Subjects Only:

8. Subjects with lymphoma as primary cancer

For Phase 2 Subjects Only:

9. Subjects unable or unwilling to consent to the provision of resected tissue after
surgery
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02765165      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740